Updating the lynch
Jan Mac Donald, MHRA group manager for access and information for medicines and standards (AIMS) in vigilance and risk management of medicines, said in a statement: "The move to make the Colourstart Test more widely accessible will make it easier for people to screen for allergy to hair colourant and to avoid suffering skin reactions if they are allergic to PPD."Wider availability of medicinal products and improved patient access and choice remain high on the health agenda.In a statement, Professor Gillian Leng, deputy chief executive and director of health and social care at NICE said: "There is currently no gold standard test for asthma which makes diagnosing a particularly difficult task for clinicians."It’s important that GPs take the appropriate steps to avoid misdiagnosing the condition, which can lead to overtreatment."This is where the report is likely to be criticised because it has not considered the effects of specific types of saturated fatty acids; but this was not part of the scope of the report – which is already a huge piece of work." She continued: "The fact is that if we are to succeed in reducing saturated fat intakes from current levels [of] around 13.5% to 10%, it is going to be extremely hard to do so without reducing saturated fat from dairy or meat." Prof Naveed Sattar, professor of metabolic medicine at the University of Glasgow, noted that: "The saturated fat question continues to be debated and so it is nice to see an updated impartial and objective look at the best available evidence, including from randomised trials."That the evidence continues to suggest saturated fats increase cholesterol and the risk of heart disease remains clear, and there is no evidence for the opposite view.NHS England's revised guidance from the Regional Medicines Optimisation Committee issued in June states: "The prescribing of liothyronine is only supported if initiated by, or considered appropriate following a review by, an NHS consultant endocrinologist.
Now, in a draft update to colorectal cancer guidelines issued for consultation, NICE is recommending daily aspirin taken for longer than 2 years to reduce colorectal cancer risk.
NICE wasn't able to recommend an ideal dose but said 150 mg or 300 mg is commonly used in current practice.
Asprin doesn't have marketing authorisation for bowel cancer prevention, so NICE is telling doctors to get informed patient consent for prescribing decisions, and to document the process.
Please see our Commenting Guide for further information.
We reserve the right to remove posts at our sole discretion.